{"id":"grazoprevir-elbasvir-ribavirin","safety":{"commonSideEffects":[{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Grazoprevir is a NS3/4A protease inhibitor that blocks the proteolytic activity of the NS3/4A enzyme, preventing viral replication. Elbasvir is a NS5A inhibitor that binds to the NS5A protein, disrupting its function and preventing viral replication.","oneSentence":"Grazoprevir/elbasvir is a combination of two antiviral drugs that inhibit the HCV NS3/4A protease and NS5A protein, respectively, to treat hepatitis C virus infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:21.143Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection in adults with compensated liver disease, including cirrhosis"}]},"trialDetails":[{"nctId":"NCT02940496","phase":"PHASE2","title":"Pembrolizumab (MK-3475) in Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-12-09","conditions":"BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatitis C Infection","enrollment":15},{"nctId":"NCT02890719","phase":"PHASE3","title":"Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.","status":"WITHDRAWN","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2016-08-03","conditions":"Liver Transplantation, Hepatitis C","enrollment":""},{"nctId":"NCT04048850","phase":"","title":"Zepatier in Patients with Substance Use","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2019-09-20","conditions":"Hepatitis C, Hiv, Coinfection, HIV","enrollment":25},{"nctId":"NCT02743897","phase":"PHASE1, PHASE2","title":"Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2016-05-01","conditions":"End Stage Renal Disease","enrollment":62},{"nctId":"NCT03797066","phase":"PHASE4","title":"ATTIC - Access To Treat in the Community","status":"TERMINATED","sponsor":"King's College Hospital NHS Trust","startDate":"2019-03-23","conditions":"Hepatitis C, Chronic","enrollment":13},{"nctId":"NCT03724149","phase":"PHASE1, PHASE2","title":"Transplanting Hepatitis C Lungs Into Negative Lung Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2018-12-12","conditions":"Lung Diseases","enrollment":10},{"nctId":"NCT03144440","phase":"","title":"Real World Experience of Chronic Hepatitis C (CHC) Treatment in Israel","status":"COMPLETED","sponsor":"Carmel Medical Center","startDate":"2016-12-13","conditions":"Hepatitis C","enrollment":200},{"nctId":"NCT03365635","phase":"PHASE4","title":"Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2019-09-22","conditions":"Hepatitis C, Hemodialysis, Nosocomial Infection","enrollment":6},{"nctId":"NCT02786537","phase":"PHASE4","title":"Study of Oral Treatments for Hepatitis C","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-06","conditions":"Chronic Hepatitis C","enrollment":1275},{"nctId":"NCT03146741","phase":"PHASE1, PHASE2","title":"Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2017-05-16","conditions":"Heart Failure","enrollment":20},{"nctId":"NCT02105701","phase":"PHASE3","title":"Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-06-05","conditions":"Hepatitis C Infection","enrollment":420},{"nctId":"NCT01717326","phase":"PHASE2","title":"A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-02-07","conditions":"Hepatitis C","enrollment":573},{"nctId":"NCT01932762","phase":"PHASE2","title":"Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-01","conditions":"Hepatitis C","enrollment":98},{"nctId":"NCT04546802","phase":"PHASE3","title":"HepATocellular Cancer Hcv Therapy Study","status":"WITHDRAWN","sponsor":"Bayside Health","startDate":"2019-09","conditions":"Hepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma","enrollment":""},{"nctId":"NCT02945150","phase":"PHASE4","title":"Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-02-01","conditions":"Renal Failure","enrollment":8},{"nctId":"NCT02895958","phase":"PHASE4","title":"The Dublin Zepatier Study","status":"TERMINATED","sponsor":"Mater Misericordiae University Hospital","startDate":"2018-03-15","conditions":"Hepatitis C","enrollment":3},{"nctId":"NCT02601573","phase":"PHASE2","title":"Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-05","conditions":"Hepatitis C","enrollment":101},{"nctId":"NCT04047680","phase":"","title":"eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-02","conditions":"Hepatitis C, Renal Disease, Viral Hepatitis C","enrollment":441},{"nctId":"NCT03423641","phase":"","title":"An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2011-01-01","conditions":"Hepatitis C, Chronic","enrollment":33808},{"nctId":"NCT02332720","phase":"PHASE2","title":"Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-01-28","conditions":"Hepatitis C","enrollment":413},{"nctId":"NCT02332707","phase":"PHASE2","title":"Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-01-22","conditions":"Hepatitis C","enrollment":443},{"nctId":"NCT03887637","phase":"","title":"Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-03-30","conditions":"Chronic Hepatitis C","enrollment":180},{"nctId":"NCT03026023","phase":"PHASE4","title":"Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant","status":"WITHDRAWN","sponsor":"Raymond T. Chung, MD","startDate":"2018-08-01","conditions":"Cardiac Transplant Disorder, Hepatitis C","enrollment":""},{"nctId":"NCT03098121","phase":"PHASE4","title":"Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infection","status":"COMPLETED","sponsor":"Taoyuan General Hospital","startDate":"2017-10-20","conditions":"Chronic Hepatitis C","enrollment":40},{"nctId":"NCT02358044","phase":"PHASE3","title":"Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-02-27","conditions":"Hepatitis C","enrollment":257},{"nctId":"NCT02105454","phase":"PHASE2","title":"Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-23","conditions":"Hepatitis C Virus","enrollment":79},{"nctId":"NCT02781649","phase":"PHASE4","title":"Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2016-07-20","conditions":"End-Stage Renal Disease, Hepatitis C","enrollment":10},{"nctId":"NCT02785666","phase":"PHASE3","title":"Swiss HCVree Trial","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2016-06","conditions":"Hepatitis C, HIV","enrollment":150},{"nctId":"NCT03105349","phase":"PHASE4","title":"A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A","status":"WITHDRAWN","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2017-07-01","conditions":"HCV","enrollment":""},{"nctId":"NCT03433326","phase":"","title":"Grazoprevir and Elbasvir Without Ribavirin for 12 Weeks in Patients With HCV-related Cryoglobulinemic Nephropathy","status":"UNKNOWN","sponsor":"University of Florence","startDate":"2018-03-01","conditions":"Hepatitis C, Cryoglobulinaemic Glomerulonephritis","enrollment":45},{"nctId":"NCT03359746","phase":"PHASE4","title":"Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant","status":"UNKNOWN","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2017-12-15","conditions":"Hepatitis C","enrollment":40},{"nctId":"NCT02647632","phase":"PHASE2","title":"Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2016-01","conditions":"Hepatitis C","enrollment":26},{"nctId":"NCT02057003","phase":"","title":"Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients","status":"UNKNOWN","sponsor":"Valme University Hospital","startDate":"2012-01","conditions":"Hepatitis C, Chronic, Human Immunodeficiency Virus","enrollment":1000},{"nctId":"NCT02732405","phase":"PHASE3","title":"Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis","status":"UNKNOWN","sponsor":"Istituto Clinico Humanitas","startDate":"2016-05","conditions":"Hepatitis C, Compensated Cirrhosis","enrollment":120},{"nctId":"NCT02204475","phase":"PHASE3","title":"Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-11","conditions":"Hepatitis C","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zepatier, Rebetol"],"phase":"phase_3","status":"active","brandName":"grazoprevir/elbasvir, ribavirin","genericName":"grazoprevir/elbasvir, ribavirin","companyName":"University of Zurich","companyId":"university-of-zurich","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Grazoprevir/elbasvir is a combination of two antiviral drugs that inhibit the HCV NS3/4A protease and NS5A protein, respectively, to treat hepatitis C virus infection. Used for Chronic hepatitis C virus (HCV) infection in adults with compensated liver disease, including cirrhosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}